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ABSTRACT
Objective: This study aimed to develop an analytical method for determining metformin concentrations in human dried blood spots (DBS) using 
optimal chromatographic conditions and DBS preparation methods and validate the analytical methods.
Methods: Analysis metformin HCl performed using C-18 columns (250 mm × 4.6 mm) at a column temperature of 40°C with a mobile phase acetonitrile 
phosphate buffer (40:60% v/v) at pH 7.0 using a flow rate of 0.8 mL/min, a photodiode array detector at a wavelength of 234 nm, and atorvastatin 
calcium as an internal standard. Samples were prepared by protein precipitation with 60% methanol and then drying using nitrogen gas at 60°C for 
15 min before reconstituting in 200 µL of the mobile phase.
Results: Invalidation procedures, the present methods met the acceptance criteria stated in the EMEA Bioanalytical Guideline 2011. The method was 
also linear at the concentration range of 25.0–5000.0 ng/mL (r=0.9997).
Conclusion: The developed method for determination of metformin HCl in DBS sample was valid with a concentration range of 25.0–5000.0 ng/mL 
and can be applied to in vivo studies.
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INTRODUCTION
In 2012, diabetes caused 1.5 million deaths globally, and high glucose 
levels contributed to 2.2 million deaths by increasing the risk of 
cardiovascular diseases and other disorders. Among these 3.7 million 
deaths, 43% were of people <70 years old and were considered 
premature. In Indonesia, premature deaths account for 48,300 of 
99,400 diabetes-related deaths annually [1].
Metformin is a biguanide medicine that lowers glucose levels by 
reducing hepatic glucose production and intestinal glucose absorption. 
Metformin is the most prescribed drug for type 2 diabetes and is the 
drug of choice for diabetes patients with obesity [2]. Metformin is also 
present in the List of National Essential Medicines according to the 
Indonesian Ministry of Health. Hence, metformin is the most needed 
medicine and must be made available at all health facilities.
Pharmacokinetics studies can be performed using plasma, serum, or 
whole blood, although most studies are performed with plasma or 
serum samples because these are easy to prepare. However, the use 
of these two matrices requires the inconvenient collection of blood 
samples from patients. In the past few years, a new sampling method 
has been developed using dried blood spot (DBS) samples on filter 
paper. Such DBS methods offer improved convenience for patients 
because they require a small volume of blood [3]. Therefore, DBS 
methods may facilitate the implementation of pharmacokinetics or 
bioequivalence (BE) tests for metformin and other medicines because 
blood sampling is minimal and does not require the imposition of deep 
wounds with the entry of needles or catheters [4].
Analyzes of metformin in DBS samples will require high selectivity and 
sensitivity due to minimal amounts of blood collected from peripheral 
sites. Some high-performance liquid chromatography (HPLC) methods 
have been developed for analyzes of DBS samples. HPLC is also 
commonly available in laboratories and is applicable to BE and other 
clinical tests. Since HPLC can be combined with various detectors, its 
uses can be adjusted to suit available tools. Herein, we used photodiode 
array (PDA) detectors that can perform rapid analyzes at several 
wavelengths [2].
In drug compound analyses, sample preparation is the most important 
part. Thus, extraction from DBS samples was conducted and 
extracts were dissolved in the mobile phase. To optimize the results, 
protein precipitation was performed, and we used a polar solvent to 
accommodate the polar properties of metformin, as shown in previous 
analyzes using HPLC methods [2].
Quantitative analyzes were performed using an internal standard with 
the similar chemical properties as the analyte, and this was added to 
samples with as yet unknown concentrations of analyte. In previous 
analyzes of metformin, diazepam, phenformin HCl, salbutamol, calcium 
atorvastatin, and ranitidine HCl were used as internal standards. In this 
study, we used calcium atorvastatin because it has a similar retention 
time to that of metformin HCl, is readily available, and can be used 
with a known and validated correction factor to determine analyte 
concentrations in unknown samples [5].
The methods used herein were modified from the reverse phase HPLC 
procedures reported by AbuRuz et al., in 2006, and were optimized 
for determinations of metformin HCl in DBS. After selecting optimal 
conditions, then validated the method based on the Bioanalytical 
Guidelines of the European Medicines Agency (EMEA; 2011) [6]. 
Measured parameters included selectivity, linearity, accuracy, precision, 
stability, recovery, and carry-over. The methods developed herein are 
expected to be used in pharmacokinetics tests, BE tests, and in other 
clinical tests of diabetic patients receiving metformin HCl therapy.
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MATERIALS AND METHODS
Materials
Metformin HCl and calcium atorvastatin were purchased from British 
Pharmacopoeia (BP), orthophosphoric acid (Merck), HPLC grade 
methanol (Merck), sodium dihydrogen phosphate (Merck), acetonitrile 
(Merck), Aquabidestilata (Ikapharmindo), filter paper (Perkin Elmer), 
human blood (Indonesian Red Cross Society), Instrumentation HPLC, 
a C-18 column (Waters, SunFireTM 5 µm; 250 × 4.6 mm), and a PDA 
detector (Waters 2996).
Standard solution
Metformin HCl was carefully weighed to 10.0 mg and was then dissolved 
with Aquabidestilata sterilized water in 10.0 mL volumetric flasks to a 
concentration of 1.0 mg/mL. The internal standard calcium atorvastatin 
was carefully weighed to 10.0 mg and was then dissolved in methanol in 
10.0 mL volumetric flasks to a concentration of 1.0 mg/mL. Dilutions were 
then performed to generate solutions with a range of concentrations.
Optimization of chromatographic condition
Mixtures containing 10.0-µg/mL HCl metformin and 10.0-µg/mL calcium 
atorvastatin were injected in 20-µL aliquots into the HPLC instrument 
and responses were observed. Optimization began with the selection of 
an optimal wavelength using the PDA detector. Metformin HCl analyzes 
were performed using the wavelength maxima at 234 nm. Sodium dodecyl 
sulfate (SDS) was used to provide ion pairs, and SDS concentrations were 
optimized at 2, 3, and 10 mM. The mobile phase composition and phosphate 
buffer pH were then optimized, and the best flow rate was established. To 
optimize the mobile phase, acetonitrile phosphate buffer ratios of 30:70, 
40:60, and 35:65 were tested with pH values of 6.0, 6.5, and 7.0. Flow rates 
were optimized by comparing 0.8, 1.0, and 1.2 mL/min.
System suitability tests
After determining optimum conditions for metformin HCl analysis, 
mixed solutions of metformin HCl and internal standard were injected 
6 times and coefficients of variation (CV) for retention times and areas 
under the curve for each substance were then calculated as PAR, which 
should be <2.0%.
Optimization of DBS sample preparation
DBS sample preparation and extraction of metformin HCl were 
conducted using the protein precipitation method. Protein precipitation 
was performed by adding 50 µL of 10 µg/mL calcium atorvastatin to 
DBS samples containing metformin HCl at a concentration of 1 µg/mL. 
Subsequently, 1.0-mL aliquots of distilled water, 60% methanol, 95% 
methanol, 100% acetonitrile, and acetonitrile formic acid (90:10) were 
added to these samples, and selected mixtures were used to optimize 
volumes of extraction solvent at 0.2, 0.5, 0.7, and 1.0 mL. Sonication 
times were then optimized by comparing samples after 5-, 10-, and 
15-min sonication. Finally, the evaporation step was optimized, and 
aliquots of up to 100.0 µL were injected into the HPLC.
Validation of metformin HCl methods for DBSs
Full validation of analytical methods for metformin HCl in DBS was 
conducted, with the parameters selectivity, carry-over, lower limit of 
quantitation (LLOQ), linearity of calibration curve, accuracy, precision 
and recovery, dilution integrity, and stability.
RESULTS AND DISCUSSION
Optimization of chromatography conditions
Initially, we optimized detection wavelengths for metformin HCl and 
then adjusted the SDS concentration to 10 mM for optimal provision 
of an ion pair that acts perfectly with metformin HCl. The mobile 
phase was optimized to maximize peak responses of the combination 
of acetonitrile phosphate buffer (40:60; pH 7.0). Mixing of the mobile 
phase was also optimized because it can affect the pH of the phosphate 
buffer and influence reactions between metformin HCl and SDS ion 
pair [7-11]. The preferred mixing method involved manual mixing by 
the analyst. Finally, the flow rate was optimized to 0.8 mL/min.
Metformin HCl was detected using a PDA detector at 234 nm after 
elution from a C-18 column (Waters, SunFireTM 5 µm; 250 mm × 4.6 mm) 
under optimal conditions. These included a mobile phase of acetonitrile 
phosphate buffer (pH 7.0; 40:60) at a flow rate of 0.8 mL/min and 
column temperature of 40°C using calcium atorvastatin as an internal 
standard. These analytical conditions produced the best separation 
parameters, including the largest area values, relatively quick retention 
times, a tailing factor close to 1, a resolution (R) of >2, the largest 
theoretical (N) plate, and an HETP value that was close to zero.
System suitability test
After identifying optimal conditions, system suitability tests were 
conducted with six injections and retention time, area under the curve, 
and PAR were obtained with a CV of <2.0%. Retention time of metformin 
is 6.872 min and retention time of atorvastatin is 7.869 min (Fig. 1).
Optimization of DBS sample preparation
Preparation or extraction of metformin HCl was conducted using the 
protein precipitation method. The protein precipitation solvents used 
were the polar solvents methanol and acetonitrile and 60% methanol 
gave the highest peak analyte and internal standard responses. This was 
due to the highly polar nature of metformin HCl, which led to greater 
solubility in a polar solvent. Further studies with the selected solvent 
were performed to optimize the amount of solvent volume added, the 
sonication time, and the evaporation step. The optimum sonication 
time was 10 min, and longer agitation times caused degradation of the 
analyte. The evaporation step was then optimized to produce a sharper 
peak (Fig. 2).
Fig. 1: Chromatogram in system suitability test
Fig. 2: Chromatogram of dried blood spots extracted blanks
Fig. 3: Chromatogram of metformin HCl at the upper limit of 
quantitation concentration of 5000 ng/Ml
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Validation of metformin HCl methods in DBSs
Selectivity
Analyzes of selectivity were performed on blank and LLOQ concentrations 
using blood from six different sources. The results showed no interference 
with internal standard or with impurities at the retention time of analyte.
Carry-over
Carry-over tests showed no carry-over effects in blanks after the 
highest concentration (upper limit of quantitation) of metformin HCl 
was injected (Fig. 3). The carry-over percentage met the requirement 
(<20%) for analytes, as shown in Table 1.
Calibration curve and LLOQ
The calibration curve was linear and had a correlation coefficient 
(r) of >0.999 in the concentration range of 25.0–5000.0 ng/mL. The 
concentration of the LLOQ of metformin HCl was 25.0 ng/mL, with a 
CV of 10.72% and a percentage difference of - 14.36%–14.10% (Fig. 4).
Accuracy, precision, and recovery
Estimates of accuracy are based on the proximity of measurements 
with actual concentrations (bias), whereas those of precision are based 
on repeatability of determinations (CV). Accuracy and precision tests 
were conducted within and between runs using concentrations that 
corresponded with the LLOQ, quality control low (QCL), quality control 
mid, and quality control high (QCH). Accuracy and precision data from 
within and between days are shown in Table 2.
The recovery test was performed by comparing analytical peak 
responses in DBS with those of standard solution at the same 
concentrations (Table 3).
Dilution integrity
Dilution integrity tests were conducted to assess accuracy, precision, 
and reliability of dilution processes during bioanalysis. If in vivo 
measurements of metformin HCl levels in biological matrices exceed 
the upper limit of 5000 ng/mL, then dilution to within the range of the 
calibration curve is required. The results of dilution integrity tests are 
shown in Table 4.
Stability
The stability of metformin HCl was tested to determine whether 
degradation occurred during storage. Stability tests were performed by 
analyzing QCL and QCH samples with three replicates for each sample. 
In short-term stability tests, samples were stored at room temperature 
and were stable after 0, 6, and 24 h. The results shown in Table 5 
indicate that metformin HCl samples are stable during storage at room 
temperature for at least 24 h.
In long-term stability tests, samples were stored at room temperature 
with desiccants for 7–45 days. These tests showed that metformin 
Table 1: Data from carry‑over measurements













CV (%) Bias (%) Measured concentration 
(average±SD; ng/mL)
CV (%) Bias (%)
25.0 25.68±1.88 7.31 2.73 26.32±2.52 9.58 5.26
75.0 76.49±0.95 1.24 1.99 78.92±3.46 4.38 5.22
2500 2520.61±72.19 2.86 0.83 2473.21±78.59 3.18 −1.07
3750 3885.96±89.01 2.29 3.62 3909.65±119.14 3.05 4.26
Table 3: Recovery of metformin HCl
Actual concentration (ng/mL) Amount of replication Recovery (average±SD; %) CV (%)
75.0 3 77.48±0.83 1.07
2500 3 77.22±0.12 0.16
3750 3 77.88±1.21 1.55








CV (%) Bias (%) Measured concentrations 
(average±SD; ng/mL)
CV (%) Bias (%)
3750 ½ 3844.45±68.81 1.79 2.52 3838.72±67.76 1.77 2.36
1875 ¼ 1939.23±76.26 3.93 3.43 1940.78±50.95 2.63 3.51
Fig. 4: Chromatogram of metformin HCl at the lower limit of 
quantitation concentration of 25.0 ng/mL
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HCl samples are stable at room temperature for at least 45 days in the 
presence of desiccants (Table 6).
To determine the stability of metformin HCl in the autosampler after 
preparation of DBS samples, post-preparation stability tests were 
necessary for 24 h at the autosampler temperature. As shown in 
Table 7, HCl metformin preparations were stable for at least 24 h in the 
autosampler.
Short-term stability tests of standard metformin HCl and internal 
standard solution were conducted at room temperature for 24 h, and 
long-term stability tests of standard solution were performed after 
storage at −80°C for 7–45 days. The resulting percentage difference 
for the stability of metformin HCl stock solution was - 1.95%–0.27% 
and that for calcium atorvastatin stock solution was - 1.76%–0.73%. 
These data suggest that stock solutions of metformin HCl and calcium 
atorvastatin are stable at room temperature for at least 24 h and at −80 
°C for 45 days.
CONCLUSION
The developed method for determination of metformin HCl in DBS 
sample was valid in the range of concentration of 25.0–5000.0 ng/mL 
and can be applied to in vivo studies. Moreover, metformin HCl samples 
are stable during storage at room temperature for at least 24 h and 
stock solutions of metformin HCl and calcium atorvastatin are stable at 
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Table 5: Short‑term stability of metformin HCl in DBS at room temperature
Hour QCL 75.0 ng/mL QCH 3750 ng/mL
Measured concentrations  
(average±SD; ng/mL)
CV (%) Bias (%) Measured concentrations 
(average±SD; ng/mL)
CV (%) Bias (%)
0 73.82±1.51 2.05 −1.58 3869.06±44.50 1.15 3.17
6 71.37±2.00 2.80 −4.84 3829.97±17.64 0.46 2.13
24 74.99±0.74 0.98 −0.02 3827.45±4.53 0.12 2.06
Table 6: Long‑term stability of metformin HCl in DBS at room temperature
Day QCL 75.0 ng/mL QCH 3750 ng/mL
Measured concentrations 
(average±SD; ng/mL)
CV (%) Bias (%) Measured concentrations 
(average±SD; ng/mL)
CV (%) Bias (%)
0 75.40±1.48 1.96 0.53 3787.54±43.52 1.15 1.00
7 73.46±0.34 0.47 −2.05 3776.92±27.36 0.72 0.72
45 71.81±1.05 1.46 −4.25 3823.65±33.46 0.88 1.96
Table 7: Post‑preparation stability (autosampler) of metformin HCl in DBS
Hour QCL 75.0 ng/mL QCH 3750 ng/mL
Measured concentrations 
(average±SD; ng/mL)
CV (%) Bias (%) Measured concentrations 
(average±SD; ng/mL)
CV (%) Bias (%)
0 75.40±1.48 1.96 1.60 3787.54±43.52 1.15 1.00
24 72.82±0.27 0.37 −2.91 3672.88±17.57 0.48 2.05
